FibroBiologics Statistics
Total Valuation
FibroBiologics has a market cap or net worth of $5.12 million. The enterprise value is $5.74 million.
| Market Cap | 5.12M |
| Enterprise Value | 5.74M |
Important Dates
The next estimated earnings date is Thursday, July 30, 2026, after market close.
| Earnings Date | Jul 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
FibroBiologics has 5.40 million shares outstanding. The number of shares has increased by 58.66% in one year.
| Current Share Class | 5.40M |
| Shares Outstanding | 5.40M |
| Shares Change (YoY) | +58.66% |
| Shares Change (QoQ) | +25.39% |
| Owned by Insiders (%) | 5.92% |
| Owned by Institutions (%) | 11.82% |
| Float | 4.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.07 |
| P/TBV Ratio | 1.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.59, with a Debt / Equity ratio of 0.95.
| Current Ratio | 1.59 |
| Quick Ratio | 0.81 |
| Debt / Equity | 0.95 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -82.63 |
Financial Efficiency
Return on equity (ROE) is -754.75% and return on invested capital (ROIC) is -147.71%.
| Return on Equity (ROE) | -754.75% |
| Return on Assets (ROA) | -123.72% |
| Return on Invested Capital (ROIC) | -147.71% |
| Return on Capital Employed (ROCE) | -418.25% |
| Weighted Average Cost of Capital (WACC) | 9.22% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.25M |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.33% in the last 52 weeks. The beta is 1.15, so FibroBiologics's price volatility has been higher than the market average.
| Beta (5Y) | 1.15 |
| 52-Week Price Change | -92.33% |
| 50-Day Moving Average | 1.10 |
| 200-Day Moving Average | 5.14 |
| Relative Strength Index (RSI) | 48.11 |
| Average Volume (20 Days) | 210,911 |
Short Selling Information
The latest short interest is 137,027, so 2.54% of the outstanding shares have been sold short.
| Short Interest | 137,027 |
| Short Previous Month | 135,591 |
| Short % of Shares Out | 2.54% |
| Short % of Float | 2.89% |
| Short Ratio (days to cover) | 1.07 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -17.19M |
| Pretax Income | -18.68M |
| Net Income | -18.68M |
| EBITDA | -16.93M |
| EBIT | -17.19M |
| Earnings Per Share (EPS) | -$6.87 |
Balance Sheet
The company has $1.48 million in cash and $2.48 million in debt, with a net cash position of -$996,000 or -$0.18 per share.
| Cash & Cash Equivalents | 1.48M |
| Total Debt | 2.48M |
| Net Cash | -996,000 |
| Net Cash Per Share | -$0.18 |
| Equity (Book Value) | 2.60M |
| Book Value Per Share | 0.74 |
| Working Capital | 1.08M |
Cash Flow
In the last 12 months, operating cash flow was -$15.48 million and capital expenditures -$219,000, giving a free cash flow of -$15.70 million.
| Operating Cash Flow | -15.48M |
| Capital Expenditures | -219,000 |
| Depreciation & Amortization | 257,000 |
| Net Borrowing | 1.22M |
| Free Cash Flow | -15.70M |
| FCF Per Share | -$2.91 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FibroBiologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -58.66% |
| Shareholder Yield | -58.66% |
| Earnings Yield | -393.79% |
| FCF Yield | -331.01% |
Analyst Forecast
The average price target for FibroBiologics is $13.50, which is 1,324.50% higher than the current price. The consensus rating is "Buy".
| Price Target | $13.50 |
| Price Target Difference | 1,324.50% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 30, 2026. It was a reverse split with a ratio of 1:20.
| Last Split Date | Mar 30, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |